Powered by Blogger.

Monday, 22 August 2016

Healthcare M2M Market: Growing Demand from Asia Pacific to Expand Market at 22.5% CAGR during 2015-2023

Innovation and simplicity in healthcare data management will be a key factor for the global healthcare M2M market in the coming years. Transparency Market Research states that companies will develop cloud-based ecosystems to keep up with the inflow of data along with ensuring its flawless management to keep in line with this trend. For instance, GE Healthcare launched its “GE Health Cloud” in November 2015, which promises to lend flexibility and ease in managing large volumes of healthcare data. 


The key players leading the global healthcare M2M market are Vodafone Plc, AT&T, Inc., and Telefonica S.A. with their own M2M platforms. “Companies will also try to reduce the gap between patients and physicians to increase their brand presence,” said the author of this research report. To maintain the brand value companies will enter strategic alliances that will help them update their platforms in the near future. How these companies incorporate technologies to make healthcare extremely accessible and accurate to the everyday user will remain the focal point of this market in the coming years.

Need to Add Accuracy to Healthcare Pushes Adoption of Healthcare M2M Platforms

Statistics by World Health Organization (WHO) indicate that as of 2014 there was a deficit of 7.2 million healthcare professionals across the globe to cater to the medical needs of the population. Researchers predict that this gap will widen by 2.5% with each passing year. The need to bridge this gap between demand and supply is expected to boost the adoption of M2M solutions in the overall healthcare industry.

The increasing administrative work that is escalating the operational costs of healthcare facilities is also coaxing managements to utilize M2M-based solutions. Not only are these solutions cost-effective but also bring in efficiency by eliminating the cumbersome paperwork. These solutions also reduce the risk of medical errors and are thus known to deliver accurate results.

Alternate Technologies Interfere with Successful Deployment Healthcare M2M

The large-scale deployment of M2M solutions in the healthcare industry is being hampered by the presence of alternate technologies such as IMAX, Satellite, 2G/3G, and Bluetooth. The wireless standards of these technologies differ, making it exceptionally difficult for adopting M2M across the sprawling healthcare sector. As the wireless technology still remains in the nascent stage in the developing countries such as Africa, the global usage of M2M solutions is expected to take time.
Smart healthcare has a huge potential to grow in the near future due to the proliferation of Internet of Things (IoT) in the majority of sectors. Developing regions that are focusing on patient-centric health that ensure efficient treatment procedures will also open up new growth opportunities for the global healthcare M2M market in the near future.

According to Transparency Market Research, the opportunity in the global healthcare M2M market was worth US$1,562.4 mn in 2014 and is expected to reach US$10,052.3 mn by the end of 2023. This market will rise at a CAGR of 22.5% between 2015 and 2023. The key application segment in this market is anticipated to be sports and fitness segment as it expands at a CAGR of 26.5% between 2015 and 2023. Geographically, though North America will be a key regional contributor, Asia Pacific is estimated to growing at the fastest CAGR of 26.9% during the forecast period.

Browse Research Report on Global Healthcare M2M Market:
http://www.transparencymarketresearch.com/pressrelease/healthcare-m2m-market.htm

Friday, 19 August 2016

Cell Culture Media Market to expand at a CAGR of 8.8% between 2014 and 2022

The top three players leading the global cell culture market are Thermo Fisher Scientific, BD Biosciences, and EMD Millipore and their cumulative share in the market amounted to 52% in 2014, states Transparency Market Research in its new research report. The groundbreaking work towards developing vital biomolecules and therapeutics using cell culture techniques has put these companies on the much-deserving pedestal. In the coming years, companies will focus on manufacturing and research activities that will be driven by growing investments in a specific type of biomanufacturing process. 


“High degree of product differentiation will play a key role in determining the winning strategies of the companies in the global market,” says the lead author of this research report. Currently, companies are engaged in the development of 3D cell culture technology that delivers even more accurate results than 2D cell culture. New product launches, collaborations, and the expansion of product portfolios will be the key focus areas for players to expand their businesses in the near future.

Customization of Treatments Drives Global Market

The blurring lines between pharmaceutical and biotechnology companies have given birth to biotech companies that focus on stem cell research to design specialized treatments by personalizing medicine. The angle of specificity in treating ailments that are no longer responsive to conventional treatments has been the biggest driving factor for the global cell culture market. Additionally, the market has its hopes pinned on the growing trend of contract manufacturing, which is proving to be economically beneficial to several companies. 

The lack of competition from generic drugs, known as biosimilars, is also fostering the growth of the global market as it is nearly impossible for generic drug manufacturers to recreate unique processing of living organisms in controlled environmental conditions. The growing demand for artificial organs that are biologically engineered and used in replacement surgeries to restore the impaired parts is also spurring the growth of cell culture market.

Difficulty in Adhering to Parameters Hampers Market

The precision-driven cell culture processes are a major hindrance to the global cell culture market. Getting all the parameters such as temperature, nutrients, humidity, and aeration is exceptionally tough. Thus, the difficulty in adhering to these clauses is hampering the expansion potential of this market. Additionally, the development of alternative technologies instead of in vitro cell and tissue culture for biomanufacturing processes is likely to restrain the market size in the near future.

North America to Lead the Market during Forecast Period

According to the research report, the opportunity in the global cell culture market was worth US$6 bn in 2013 and is expected to reach a valuation of US$11.3 bn in 2022, expanding at a CAGR of 7.1% between 2014 and 2022. The cell culture media segment is anticipated to be the fastest-growing segment of the global market at a CAGR of 8.8% between 2014 and 2022. Regionally, North America led the overall market and is expected to contribute a revenue worth US$3.7 bn by 2022. Analysts predict that Asia Pacific is will be the emerging regional segment during the forecast period.

Browse Research Report on Global Cell Culture Media, Sera, and Reagents Market:
http://www.transparencymarketresearch.com/cell-culture-media-sera-reagents-market.html

Tuesday, 16 August 2016

Growing Research and Development Initiatives to Increase Adoption of Bioinformatics Services Market, reports TMR

The implementation of expansion strategies to enhance market share will increase the intensity of competitive rivalry on the global level for the existing market players, reports Transparency Market Research in a new study. To maintain their position in the global bioinformatics market, the large number of market players operating in the global bioinformatics market are investing in research and development projects. They are also looking forward towards technological advances for increasing application in biosciences and integrated information technology. The top three market players in the global bioinformatics are Affymetrix Inc., Accelrys Inc., and CLC bio A/S. They together comprise approximately 34.6% of the overall global bioinformatics market in 2014. 


The prevalence of high entry barriers is estimated to increase the rivalry between the numerous existing companies in the global bioinformatics market, making it highly fragmented. The existing companies are focusing on the implementation of acquisition strategies and collaborations in order to enhance their product portfolio and expand their market reach.

Growing Need for Technological Advancements to Augment Demand for Bioinformatics Techniques

The expansion of biotechnology applications in fields of forensic research and disease diagnosis is drawing the attention of various healthcare organizations and professionals. According to the TMR report, biotechnology with technological and process advancements tends to create high-wage job opportunities in developing and developed countries due to which governments are focusing on the growth of the biotechnology industry.

For instance, The Biotechnology Industry Organization of the United States of America promotes collaborations between industry participants, academic organizations, and state governments of the country in order to develop bioscience groups. In this regard, the state governments are also increasing the implementation of strategies and programs to create job opportunities in the field of bioscience.

Many companies have implemented reimbursement policies funded by the governments to train employees in order to fulfill the requirement of skilled employees working in the field of bioinformatics services. Thus, the initiatives taken by governments to support research and development projects and creation of jobs in the biotechnology sector are anticipated to boost the global demand for bioinformatics services.

Lack of Skilled Workforce Could Hinder Supply Side of Bioinformatics Services

For better and accurate results, it is imperative that the bioinformatics techniques are operated by skilled personnel. The need for heavy investment in installation and tools upgradation training tends to impede the growth of the industry. Due to this, there is a lack of skilled manpower in the bioinformatics sector who can adapt to sophisticated and high-end biotechnology process and techniques. The scarcity of skilled workers is hindering the growth process of large clinical laboratories as they struggle to automate their processes. On the other hand, the small and medium laboratories have amplified their efforts to abridge and boost their operations with the available resources. Research and development activities also demand highly skilled personnel, but the lack of it is obstructing the growth process making it difficult for organizations and market players to benefit from their research investments.

However, the expansion in web-based services for research and development is likely to cut down the cost of R&D processes. The web-based bioinformatics segment is projected to witness substantial growth in the upcoming years in the global bioinformatics market.

The global bioinformatics market is expected to grow at a CAGR of 15.5% between 2014 and 2020. The market was worth US$10.04 bn in 2013 and is projected to reach US$30.87 bn by the end of 2020. The drug development segment is anticipated to lead all application segments. North America is expected to maintain its dominance in the global bioinformatics market with a revenue worth US$11,927.9 mn by 2020. Asia Pacific is expected to witness the highest growth with a CAGR of 18.7% throughout the forecast period.

The review has been based on the findings of a TMR report titled, “Global Bioinformatics Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”

Browse Research Report on Global Bioinformatics Market:
http://www.transparencymarketresearch.com/bioinformatics-market.html

Tuesday, 2 August 2016

Global Medicated Pain Relieving Plasters Market Trends and Industry Analysis 2024

Medicated Pain Relieving Plasters Market: Introduction 

Medicated pain relieving plasters are piece of fabrics that contains medication along with the layers of adhesives. These plasters comprises adhesive coating that can be helful for temporary relief of major or minor aches and pains of joints and muscles. Medicated pain relieving plasters offer cost effective way to treat conditions such as back pain, arthritis, muscle ache, osteoporosis, stain, bruises and others. Capsaicin, menthol, camphor, methyl salicylate, buprenorphine, fentanyl citrate and ketoprofen are major types of medicated pain relieving plasters. These plasters effectively and quickly deliver medication through the skin to underlying tissue of the body.


Medicated Pain Relieving Plasters Market: Growth Enablers

Aging population coupled with increasing prevalence of arthritis, musculoskeletal pain and others will boost the demand for medicated pain relieving plasters globally. In addition, several advantages of medicated pain relieving plasters over oral pain killer therapeutics will augment the market growth. For example, medicated pain relieving plasters allow the drugs to be directly absorbed into the damaged soft tissue as against the systemic route followed by oral analgesics, thus speeding up the healing process.

Additionally, medicated pain relieving plasters possess only administration site-related side effects such as skin irritation, burning sensation, rash, pruritus and dermatitis depending on the patient skin condition, whereas oral painkillers carry a risk of damaging the liver, intestines or stomach and other systemic effects. Moreover, consistent efforts by key companies to provide new and advanced medicated pain relieving plasters also drive the market growth. These factors would in turn boost the demand for medicated pain relieving plasters and hence stimulates the market growth. However, high cost of medicated pain relieving plasters will restrain the market growth. For example, a five-pack of salonpas arthritis pain patches costs a patient around USD 9, while patient can buy nearly 100 Advil pills at the same price.

Medicated Pain Relieving Plasters Market: Regional Insight

In terms of geography, North America accounted for the largest market share of medicated pain relieving plasters. The market of medicated pain relieving plasters in North America is majorly driven by rising incidences of disease such as arthritis, osteoporosis and others in North America. Europe is considered as the second largest market of medicated pain relieving plasters owing to increasing acceptance of pain relieving plasters among patient population. In addition, consistent efforts of key players to expand their market presence in Europe will further stimulate the growth of medicated pain reliving market.

Asia-Pacific (majorly India and China) is the emerging market for the global medicated pain relieving plasters owing to rising interest of companies to capitalize the untapped opportunities in this region. In addition, increasing incidences of arthritis and back pain in Asia-Pacific would further stimulate the market growth. For example, According to the Emirates Arthritis Foundation, 20% of the population of the UAE was diagnosed with arthritis in 2013. Additionally, the World Health Survey conducted in Kuwait suggested that 16.1% of the population suffered from arthritis in the country in 2013. Thus, high prevalence of arthritis and back pain in these regions has led to an increase in demand for medicated pain therapies in the region.

Medicated Pain Relieving Plasters Market: Key Players

Some of the key players engaged in medicated pain relieving plasters market are Zhejiang Dingtai Pharmaceutical Co., Ltd., Hisamitsu America, Inc., DSE Healthcare Solution LLC, Zhejiang Bangli Medical Products Co., Ltd., Anhui Dejitang Pharmaceutical Co., Ltd. and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

Browse Research Report on Medicated Pain Relieving Plasters Market:
http://www.transparencymarketresearch.com/medicated-pain-relieving-plasters-market.html

Monday, 1 August 2016

Pulmonary Drug Delivery Systems Market to Expand at 4.50% CAGR Owing to Increased Prevalence of COPD and Asthma

The global pulmonary drug delivery systems market is said to be growing at a CAGR of 4.5% between 2013 and 2019, as described in a research report released by Transparency Market Research. This market was recorded at US$28.7 bn in 2019 and is expected to reach US$21.03 bn by the end of 2019. The report, titled “Pulmonary Drug Delivery Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” is the result of an extensive study of the current scenario in the market. All the information released in the report can be absorbed by market players and investors in order to execute their business decisions with improved clarity and therefore, enhanced success rate. 


According to the report, the main reason why the global pulmonary drug delivery systems market is currently growing is the increase in the prevalence of respiratory diseases around the world. These include asthma and chronic obstructive pulmonary disease. There is, therefore, a need for the global pulmonary drug delivery systems market to provide enhanced devices and treatment options that can effectively take care of today’s ailments on a larger scale. This means major advancements are being made in the formulation of drugs and their delivery systems.

The report also draws from studies conducted by global bodies such as the World Health Organization. The WHO has stated that nearly 300 mn individuals around the world are asthmatic, while almost 210 mn people are suffering from COPD. Two major reasons the WHO cites for this alarmingly high number of people with respiratory problems are the increase in the number of tobacco products consumers and the increasing rate of air pollution. Another major reason for this situation is the changes made by people to fit in to modern society, as quite a few of them are noted to be unhealthy.

The report divides the global pulmonary drug delivery systems market according to product type and application. In terms of products, the market was led by metered dose inhalers in 2012, when it accounted for 56.8% of the market. The second-largest product type in the market at the time was dry powder inhalers, while nebulizers is expected to be the fastest-growing segment in the market for the given forecast period. Metered dose inhalers could lose market share to dry powder inhalers due to their increasing demand.

The report’s geographical analysis of the global pulmonary drug delivery systems market reveals North America as being the leader in the market in terms of demand in 2012. This region’s dominance in the global pulmonary drug delivery systems market was attributed to the large number of people affected by respiratory illnesses.

Europe is expected to show a downward trend in the global pulmonary drug delivery systems market for the given forecast period, owing to austerity measures taken by governments and a high penetration rate of generic drugs. Conversely, the Asia Pacific market is expected to show a rapid rate of increase due to a high population density and a rapidly improving healthcare infrastructure. This region is also benefitting from increased medical expenditure and increasing awareness levels.

The key players in the global pulmonary drug delivery systems market are GlaxoSmithKline Plc., Philips Respironics, Inc., Omron Healthcare, Inc., Novartis AG, 3M Health Care, CareFusion Corporation, and PARI Respiratory Equipment Inc.

Browse Research Report on Pulmonary Drug Delivery Systems Market:
http://www.transparencymarketresearch.com/pulmonary-drug-delivery-systems.html

Monday, 25 July 2016

Immunoglobulin demand to drive Global Plasma Protein Therapeutics Market

Transparency Market Research has published a new market report titled, “Global Plasma Protein Therapeutics Market: (Product Type – Coagulation Factors, Immunoglobulins, Albumin, C1-esterase Inhibitors, Alpha-1 Antitrypsin, and Others; Application: Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024.” According to the report, the global plasma protein therapeutics market was valued at US$ 18.5 Bn in 2015 and is projected to reach US$ 31.8 Bn by 2024.


Plasma protein are blood-derived medicines used in wide therapeutic areas. Life threatening diseases such as chronic lymphocytic leukemia, multiple myeloma, congenital AIDS, and hemophilia are treated with plasma-derived proteins. Market related factors such as growing use of immunoglobulins in primary immunodeficiency, and wide opportunities for human albumin in treatment of burns, shock and blood loss and also as a drug formulation agent, vaccine ingredient, sealant in surgeries, and coating for medical devices and equipment. Other factors such as growing demand for plasma protein therapeutics owing to increasing development in new indications, additional application in existing indications, innovative solutions for safe and efficient plasma collection, better access to medicines in emerging markets, and new plasma-derived therapies drive the plasma protein therapeutics market.

Geographically, the global plasma protein therapeutics market has been segmented into the following regions: North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America accounted for the largest share of 40.7% of the global plasma protein therapeutics market in 2015. Intravenous immunoglobulin (IVIG) was the largest segment of the market primarily due to increasing usage in new indications, new researches, and increasing geriatric population. According to the Immune Deficiency Foundation, currently around 55,000 people in the U.S. with antibody deficiency receive PIDD treatment through IVIG. The plasma protein therapeutics market in North America will be further fueled by the increasing usage of immunoglobulins and C1 esterase inhibitors segment during the forecast period.

Europe was the second largest market for plasma protein therapeutics in 2015. This is attributed to high rate of plasma donation and growing demand for plasma protein in increasing number of indications. The intravenous immunoglobulin segment in Europe is expected to expand at an impressive CAGR during the forecast period due to increase in the number of patients with bleeding disorders and growing number of chronic inflammatory demyelinating polyneuropathy (CIPD) cases. Europe has experienced a surge in the amount of plasma collected and processed, which nearly doubled in the last decade. The immunoglobulin market continues to grow due to the increase in the number of clinical indications for IG. Germany was the leading market for plasma protein therapeutics in Europe, accounting for one-third share in 2015, followed by France, the U.K., Italy, and Spain. In terms of volume, Sweden was the largest market for plasma protein, followed by France, Spain, Italy, Switzerland, the U.K. and Germany.

Asia Pacific is projected to be the most attractive market for plasma protein therapeutics during the forecast period. The market in the region is anticipated to expand at the highest CAGR of 8.1% from 2016 to 2024. This is due to strong demand for immunoglobulin and albumin, improving health care facilities, increasing health care expenditure, and growing public awareness. China dominated the plasma protein therapeutics market in Asia Pacific. China imports 56% of its albumin supply to alleviate shortage and to decrease the demand-supply gap. Hence, albumin is projected to be the fastest growing segment in Asia Pacific. Other factors such as economic development in emerging economies such as India and China, where increase in health care expenditure and growing public awareness about immunodeficiency disorders would help the region to prevail as the most attractive market. Growing demand for IVIG in replacing absent antibodies in immune failure and treating immune deficiency, and other unmet medical needs is likely to propel the market in Asia Pacific.

Latin America is one of the largest economic regions of the future. Strong sales and market growth are expected over the medium term due to new marketing approvals for immunoglobulin and improved diagnosis rate of immunodeficiency. Companies are strengthening their regional presence in Latin America due to increasing product demand and growth opportunity in the region. Brazil is the leading market for plasma protein therapeutics in Latin America, followed by Mexico.

Key players in the global plasma protein therapeutics market are Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire plc, and China Biologics. Baxalta (acquired by Shire plc), Grifols, and CSL Behring are likely to average 7% plasma sales growth between them over the next five years.

Saturday, 23 July 2016

Prostate Cancer Treatment to Revolutionize Standard of Care and Multiple Treatment Options

Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic cancer.


Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and Xofigo (Bayer Healthcare Pharmaceutical, Inc.). The prostate cancer therapeutics market is slated to increasing rapidly in the near future owing to promising drugs in the pipeline. These drugs are expected to drive the market during the forecast period from 2015 to 2023. In 2013, Johnson & Johnson acquired Aragon Pharmaceuticals that has second generation androgen receptor signaling inhibitor (ARN-509), a highly potential drug for treatment of castration resistant prostate cancer. This acquisition is seen as a strategic move by Johnson & Johnson to mitigate the expected slowing of Zytiga sales.

Zytiga, launched in 2011, clocked sales of over USD 1 billion in 2012 and works by targeting the enzyme CYP17A1 responsible for androgen production. The drug is expected to lose its patent protection in 2016. Moreover, Zytiga is facing stiff competition from Xtandi (Astellas Pharma, Inc. / Medivation, Inc.). The Astellas’ drug has already matched the sales of Zytiga and is rapidly moving further upstream as the patients are using treatment for long period and urologists continuing to adopt the drug. High prices of newer drugs and uncertain reimbursement policies will be restraining the market to some extent. However, the growing awareness about prostate cancer, rapid urbanization, and government efforts to fund cancer treatment will drive the market during the forecast period from 2015 to 2023.

On the basis of geography, the global prostate cancer therapeutics market can be segmented into four major regions, namely, North America, Europe, Asia Pacific, and Rest of the world. American men have highest rates of prostate cancer followed the European males. It is estimated that more than 230,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. In U.K., more than 40,000 new cases are registered having prostate cancer, and about 11,000 deaths occur annually. Therefore, the global prostate cancer therapeutics market has been traditionally dominated by North America Asia region ranks lowest in terms of rate of prostate cancer.

Some of the key players in this market are Johnson & Johnson, AstraZeneca plc, Astellas Pharma, Inc., Sanofi, Medivation, Inc., Ipsen SA and Bayer Healthcare Pharmaceutical, Inc.